Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis

Motoaki Shiratsuchi, Seiichi Motomura, Yasunobu Abe, Satoshi Shiokawa, Junji Nishimura

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Systemic sclerosis (SSc) characteristically consists of fibrotic changes in various organs, and immunological abnormality is the main cause of the disease. Although high-dose immunosuppressive therapies with autologous or allogeneic hematopoietic stem cell support can reverse the disease course, they have a high treatment-related mortality. We report the successful use of nonmyeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for SSc. A 40-year-old woman with diffuse scleroderma and interstitial pneumonia underwent allogeneic peripheral blood stem cell transplantation from an HLA-identical sibling after conditioning with low-dose total-body irradiation and fludarabine. Prophylaxis for graft-versus-host disease (GVHD) consisted of cyclosporine and mycophenolate mofetil. No infection or acute GVHD developed. One year after transplantation, the patient developed membranous glomerulopathy caused by chronic GVHD that was successfully treated with prednisolone. The patient's skin score decreased dramatically, and her pulmonary function is stable 4 years after transplantation. Nonmyeloablative allogeneic HSCT may be more effective than conventional therapies for SSc.

Original languageEnglish
Pages (from-to)1207-1209
Number of pages3
JournalClinical Rheumatology
Volume27
Issue number9
DOIs
Publication statusPublished - Sep 2008

All Science Journal Classification (ASJC) codes

  • Rheumatology

Fingerprint Dive into the research topics of 'Long-term follow-up after nonmyeloablative allogeneic hematopoietic stem cell transplantation for systemic sclerosis'. Together they form a unique fingerprint.

  • Cite this